知名基金经理集中入场，公募参与定增热度再起

Core Insights - The recent surge in the private placement market has attracted significant attention, particularly with prominent fund managers participating in the Baili Tianheng private placement [1] - On September 23, China Europe Fund announced that its funds managed by Ge Lan, including China Europe Medical Health and China Europe Medical Innovation, participated in the private placement of Baili Tianheng [1] - This private placement not only highlights the focus on pharmaceutical-themed funds but also indicates that public funds remain actively engaged in seizing structural opportunities despite fluctuations in the pharmaceutical sector [1] Group 1 - The Baili Tianheng private placement has become a prominent platform for pharmaceutical funds to showcase their strategies [1] - The participation of both long-term pharmaceutical-focused funds and comprehensive growth strategy products reflects a strong enthusiasm for allocation in this private placement [1] - The event leaves room for further market performance expectations, suggesting potential future opportunities in the sector [1]